Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TCR2 THERAPEUTICS INC.

(TCRR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

TCR2 Therapeutics : TCR-2 THERAPEUTICS TO HOST R&D DAY ON OCTOBER 20, 2021

10/14/2021 | 06:41am EST

CAMBRIDGE, Mass. - TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced that it will host a virtual R&D Day for analysts and investors at 8:00a.m. ET on Wednesday, October 20, 2021.

The meeting will feature updates on the Company's emerging oncology pipeline including enhancements, novel targets and allogeneic TRuCs as well as TRuC Tregs for autoimmune diseases. Speakers will include:

Garry Menzel, Ph.D., President and Chief Executive Officer

Alfonso Quintas-Cardama, M.D., Chief Medical Officer

Robert Hofmeister, Ph.D., Chief Scientific Officer

Robert Tighe, Vice President of Translational Research

Raffit Hassan, M.D., Chief of Thoracic and GI Malignancies Branch at the National Cancer Institute

To register for the virtual event or watch a live webcast of the presentation, please visit the Investors page of the Company's website at investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR2 Therapeutics

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from cancer. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate targeting solid tumors, gavocabtagene autoleucel ('gavo-cel'), is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company's lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR2, please visit www.tcr2.com.

Contact:

Investor and Media

Carl Mauch

Director

Investor Relations and Corporate Communications

TCR2 Therapeutics Inc.

T: (617) 949-5667

E: carl.mauch@tcr2.com

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about TCR2 THERAPEUTICS INC.
11/22TCR2 Therapeutics Inc. Announces Resignation of Mayur Somaiya, Effective December 10, 2..
CI
11/11Tcr-2 therapeutics reports third quarter 2021 financial results and provides corporate ..
AQ
11/10TCR2 THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
11/10TCR2 Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate U..
PU
11/10TCR▓ Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate U..
AQ
11/10TCR2 Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
11/01TCR2 Therapeutics Announces Expansion of U.S. Manufacturing Capacity - Form 8-K
PU
11/01TCR2 THERAPEUTICS INC. : Costs Associated with Exit or Disposal Activities, Financial Stat..
AQ
11/01TCR▓ Therapeutics Announces Expansion of U.S. Manufacturing Capacity
AQ
11/01Tcr2 Therapeutics Inc. Announces Expansion of U.S. Manufacturing Capacity
CI
More news
Analyst Recommendations on TCR2 THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -100,0 M - -
Net cash 2021 246 M - -
P/E ratio 2021 -1,93x
Yield 2021 -
Capitalization 195 M 195 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 164
Free-Float 96,4%
Chart TCR2 THERAPEUTICS INC.
Duration : Period :
TCR2 Therapeutics Inc. Technical Analysis Chart | TCRR | US87808K1060 | MarketScreener
Technical analysis trends TCR2 THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 5,11 $
Average target price 24,90 $
Spread / Average Target 387%
EPS Revisions
Managers and Directors
Garry E. Menzel President, Chief Executive Officer & Director
Mayur Ian Somaiya Chief Financial Officer
Ansbert K. Gadicke Chairman
Robert Hofmeister Chief Scientific Officer
Alfonso Quintßs-Cardama Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
TCR2 THERAPEUTICS INC.-83.48%195
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-43.31%23 888